title: Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment.
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Maurizio
authors.initials: M
authors.lastname: Muscaritoli
authors.forename: Laura
authors.initials: L
authors.lastname: Cannella
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Loglisci
authors.forename: Michelina
authors.initials: M
authors.lastname: Santopietro
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001786:Blood Glucose / Q000032:analysis*; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D001786:Blood Glucose; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate